Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ociperlimab (Primary) ; Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms AdvanTIG-204
  • Sponsors BeiGene

Most Recent Events

  • 30 Apr 2025 Results (n=62) assessing baseline blood samples to identify mutations for post-treatment ctDNA MRD detection (blood-informed MRD) as well as tissue-informed MRD in 62 limited-stage small cell lung cancer (LS-SCLC) patients receiving CRT combined with IO treatments were presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 06 Mar 2024 According to BeiGene media release, data from the study will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 5-10 in San Diego.
  • 11 Aug 2023 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top